Russia prepares for shortage of anti-cancer drugs

7 April 2022

The Russian Ministry of Health has prepared a list of 39 anticancer drugs that are likely to be in short supply in the country due to ongoing military conflict between Ukraine and Russia and Western sanctions imposed on Russia, reports The Pharma Letter’s local correspondent.

Most of drugs included in the list are used to treat the most common types of cancer: melanoma, breast cancer, bronchial, lung and prostate cancer and are original drugs, which are imported from abroad. According to official state data, spending on these drugs in 2021 accounted for 62% of all public procurements on anticancer drugs in Russia last year, which is equivalent to 140 billion roubles ($1.77 billion) and 226 billion roubles respectively.

These plans have already sparked criticism from some local experts, according to whom the replacement of these original drugs by Russian analogues may throw the domestic medicine back for 20 years, as a significant part of such generics will be of significantly lower quality, compared to their foreign analogues and will be less effective for patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical